Background. Patients undergoing allogeneic stem-cell transplantation (aSCT) are at high risk of invasive fungal disease (IFD). Optimization of antifungal prophylaxis strategies may further improve patient outcomes and reduce treatment costs.

Methods. We performed a retrospective single-center pharmacoeconomic evaluation comparing patients who received posaconazole oral solution plus micafungin intravenous bridging as required (POS-MIC) to patients who received only micafungin (MIC) as antifungal prophylaxis after aSCT at the University Hospital of Cologne. Epidemiological, clinical, and direct treatment cost data extracted from the Cologne Cohort of Neutropenic Patients (CoCoNut) were analyzed. Revised 2008 EORTC/MSG criteria were used for classification of IFD.

Results. During the observation period from January 2010 to December 2015, 313 patients (97 in the POS-MIC and 216 in the MIC group) fulfilled inclusion criteria. Most patients were male (n = 174, 56%) and median age was 52 years (range: 18–75 years). Acute myeloid leukemia was the most common underlying disease (n = 146, 47%). In the POS-MIC and MIC group, median overall length of stay (LOS) was 42 days (IQR: 35–52 days) vs. 40 days (IQR: 35–49 days; P = 0.296), resulting in median overall direct treatment costs of €42,964 (IQR: 35,040–56,348) vs. €43,241 (IQR: 37,281–51,184; P = 0.507). In both groups, possible IFD occurred in six patients (6%) vs. 16 patients (7%); P = 0.696 and probable/proofed IFD occurred in five patients (5%) vs. three patients (1%; P = 0.051). Overall in-hospital mortality rates in the POS-MIC and MIC group were 10% (n = 10) vs. 4% (n = 9; P = 0.035). Kaplan–Meier analysis showed improved outcome of patients who received MIC at day 100 (P = 0.037) and at day 365 (P < 0.001) following aSCT. Multivariable Cox-regression model demonstrated treatment on ICU as the most important independent covariate for mortality at day 100 (HR: 8.08, P < 0.001) and at day 365 (HR: 4.70, P < 0.001).

Conclusion. We observed a higher mortality in patients receiving POS-MIC instead of MIC, which was not explained by breakthrough IFD. The higher drug acquisition costs of micafungin compared with posaconazole oral solution did not translate into higher overall direct treatment costs.

D. Astellas, Consultant; J. Vehreschild, Consultant; A. Brandenburg, Affiliate; J. Vehreschild, Speaker; G. J. J. M. G. T., Consultant; D. Astellas, Consultant; and G. J. J. M. G. T., Consultant. Grant Investigator and Speaker honorarium. Research grant and Speaker honorarium. Dr. M. G. J. T., Speaker and Consultant honorarium. Research grant and Speaker honorarium. Dr. M. G. J. T., Consultant and Speaker honorarium. Research grant and Speaker honorarium.

413. Intravenous and Tablet Formulation of Posaconazole in Antifungal Therapy and Prophylaxis: A Retrospective, Non-Interventional, Multicenter Analysis of Patients Treated in German Tertiary-Care Hospitals

Sebastian M. Heimann, MD, PhD; Olaf Penacik, Professor of Medicine; Werner H. Heimann, MD; Thomas Enders, MD; Gerlinde Susanne Kessel, MD; Annika Löhntert, MD; and Janne Vehreschild, PhD, Dr. Med.1

1Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany; 2Charité University Hospitals, Berlin, Germany; 3University of Würzburg Medical Center, Würzburg, Germany; 4University Hospital of Jena, Jena, Germany; 5University Hospital of Heidelberg, Heidelberg, Germany; 6Department of Internal Medicine, Infectiology, University Hospital of Frankfurt, Frankfurt/Main, Germany; 7University Hospital of Cologne, Cologne, Germany

Session: 56. Fungal Disease: Management and Outcomes

Thursday, October 4, 2018: 12:30 PM

Background. Novel formulations (gastro-resistant tablet and intravenous solution) of posaconazole (POS) have been approved in prophylaxis and therapy of invasive fungal disease (IFD). The aim of the multicenter noninterventional study was to analyze treatment strategies and clinical effectiveness of these new options.

Methods. We set up a web-based registry on the science platform www.ClinicalSurveys.net and members of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGHMO) were invited to provide clinical data on patients who received novel POS formulations. Data analysis was split into two groups of patients who received novel POS formulations for antifungal prophylaxis (posaconazole prophylaxis group) and antifungal therapy (posaconazole therapy group), respectively.

Results. One hundred eighty hospitalized patients (151 in the posaconazole prophylaxis group and 29 in the posaconazole therapy group) from six German tertiary care centers treated between July 2014 and March 2016 were included into our analysis. Seventy-three (38.9%) were female (females vs. males: n = 10, 9–177 years). Most patients (n = 111, 62%) had an acute myeloid leukemia as primary underlying disease. In the posaconazole prophylaxis group and posaconazole therapy group, mean POS serum levels at steady-state were 1,154 µg/L (n = 40, 95% CI: 939–1,369 µg/L), 1,097 µg/L (n = 32, 95% CI: 871–1,378 µg/L), respectively (P = 0.776). In the posaconazole prophylaxis group, nine (6%) possible/proven fungal breakthroughs were reported. In the posaconazole therapy group, 17 and 12 patients received POS as first-line therapy and salvage therapy, respectively. Most frequent indications were possible (n = 9) and probable (n = 7) aspergillosis and proven (n = 7) mucormycosis. The median overall duration of POS therapy was 18 days (IQR: 7–23 days). Thirteen patients (45%) had progressive IFD with treatment under novel POS formulations.

Conclusion. Our study demonstrates clinical effectiveness of antifungal prophylaxis with novel POS formulations. In patients treated for possible/probable/proven IFD, the observed tolerability and overall mortality was comparable to previous studies with other antifungals in similar patient populations.

Disclosures. S. M. Heimann, MSD: Consultant; Grant Investigator; and Research Grant and Speaker honorarium. W. J. H., MSD: Grant Investigator and Speaker’s Bureau, Research grant and Speaker honorarium. J. Vehreschild, MSD: Grant Investigator and Speaker’s Bureau, Research grant and Speaker honorarium.

414. Diagnostic Usefulness of Differential Time to Positivity (DTP) in Neutropenic Cancer Patients With Suspected Catheter-Related Candidemia (CRC)

Y. Min, MD; H. Min, MD; H. Lee, MD; S. Min, MD; J. Heo, MD; H. Han, MD; J. Heo, MD; S. Kim, MD; J. Kim, MD; J. Kim, MD; and S. Kang, MD.

Session: 56. Fungal Disease: Management and Outcomes

Thursday, October 4, 2018: 12:30 PM

Background. The decision of catheter removal in neutropenic patients with candidemia is difficult because they usually have surgically implanted catheter, and CRC are less frequent invasive fungal infections (IFIs) in these patients. However, there are limited data on distinguishing CRC from non-CRC before catheter removal. We thus evaluated the diagnostic performances of DTP to diagnose CRC in neutropenic cancer patients with suspected CRC.

Methods. All adult neutropenic cancer patients with candidemia were enrolled in a tertiary care hospital from July 2012 to December 2016. Definite CRC was defined if 215 CFUs of Candida spp. in a removed catheter tip. Probable CRC was defined if (1) one to 14 CFU in catheter tip, and clinical improvement within 48 hours after catheter removal with antifungal agent therapy or (2) the infection was refractory to antifungal therapy even after catheter removal. None of the patients were finally analyzed, excluding three indeterminate candidemia. On the basis of the receiver operating characteristics (ROC) curve, the optimal cut-off was 313 µg/L (AUC = 0.70, 95% CI: 0.65–0.74, P = 0.002), which was defined if any of the following conditions were satisfied: (1) catheter tip cultures were negative and a noncatheter source of candidemia was found by culture, (2) the catheter tip cultures within 24 h before the start of antifungal therapy were negative, and (3) the clinical improvement before or without catheter removal.

Results. DTP appears to be useful to rule in CRC in DTP > 2.145 h to be the optimal cut-off for CRC in neutropenic cancer patients.

Disclosures. All authors: No reported disclosures.

415. Breakthrough Invasive Fungal Infections in Adult Hematologic Malignancy Patients Receiving Isavuconazole Prophylaxis

Catherine Devoe, MD, Monica Kang, MD, MPH; Brian Schwartz, MD; Sarah A. Dornberg, MD; Mimi Lo, PharmD; Larissa Graff, PharmD; Marisa Tan, PharmD; Aaron Logan, MD, PhD; Jennifer Babk, MD, PhD; and Peter Chin-Hong, MD.

Session: 56. Fungal Disease: Management and Outcomes

Thursday, October 4, 2018: 12:30 PM

Background. Isavuconazole (ISA) is a novel triazole antifungal approved for treatment of invasive fungal infections in hematology malignancy patients when other azoles are contraindicated, there are currently limited data on breakthrough invasive fungal infection (IFI) rates in this context.

Methods. We retrospectively reviewed inpatient and outpatient pharmacy records from March 2015 to April 2018 to identify adult patients with hematologic malignancy who received at least 7 days of ISA for prophylaxis. Breakthrough IFI was defined by EORTC-MSG criteria.

Results. We identified 73 hematologic malignancy patients who received ISA; 29 received at least 7 days ISA for prophylaxis in 33 separate episodes. Of these patients, 52% had acute myeloid leukemia, 14% had acute promyelocytic leukemia, 10% had myelodysplastic syndrome, and 21% had another malignancy. Eighty-six percent of these patients were neutropenic (median duration 24 days, range 2–213). Median duration of ISA prophylaxis was 61 days (range 8–635). The most common reason for choosing ISA over other antifungal agents was QTc prolongation (45%), followed by intolerance of other antifungals (27%) and drug-drug interactions with other azoles (21%). Patients (12%) developed proven or possible breakthrough IFI (Table 1). Among patients with breakthrough IFI, mortality was 50% at 12 weeks.

Disclosures. None.